A Single Arm, Open Label Study of First Line Treatment With Tarceva Plus Avastin on Progression-free Survival in Patients With Advanced or Metastatic Liver Cancer.
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2014
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Roche
- 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2010 Planned end date changed from 1 Oct 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned number of patients changed from 49 to 51 as reported by ClinicalTrials.gov.